Igor Grachev, M.D., Ph.D., joined Marinus as vice president, clinical development and brings nearly 20 years of Pharma industry experience to Marinus Pharmaceuticals.

Dr. Grachev has led clinical development and medical affairs programs at both multinational pharmaceutical and biotech organizations. Prior to joining Marinus, he served as Chief Medical Officer at Cellectar Biosciences, and previously had progressive leadership roles at TEVA Branded Specialty Pharmaceuticals, Novartis, GSK, GE Healthcare, BioClinica, Merck, Sanofi-Aventis, Schering Plough, and Guide Pharmaceutical Consulting. Over the course of his career, Dr. Grachev has been responsible for clinical development, clinical operation, regulatory affairs, medical affairs and drug safety, execution and management of clinical programs and trials Phases 1 through four worldwide in neurology/neurodegenerative disorders and psychiatry, neuro-oncology and other adjacent therapeutic areas, achieving regulatory approvals in multiple countries.

Dr. Grachev is a former assistant professor at SUNY Upstate Medical University and served as a fellow/instructor/assistant professor at Massachusetts General Hospital, Harvard University Medical School. Dr. Grachev is well-published in the field of neurology, neurodegeneration and psychiatry with over 150 peer-reviewed publications. He is also the editor-in-chief of the Journal of Neurology and Brain Disorders and serves as associate editor of several neurology and medical journals. Dr. Grachev earned his M.D. with highest honor in general medicine from Bogomolets National Medical University; his Ph.D. in neuroscience, and neurology and psychiatry residency trainings from the Institute of Gerontology at the Shupyk National Medical Academy of Postgraduate Education; and completed a fellowship training at Massachusetts General Hospital, Harvard University Medical School.